March 2021 - Cancer Currents Blog
-
New on NCI’s Websites for March 2021NCI periodically provides updates on new websites and other online content of interest to the cancer community. See selected content that has been added as of March 2021.
-
Targeted Therapy Cabozantinib Slows Progression of Rare Kidney CancerCabozantinib (Cabometyx) is an effective initial treatment for people with metastatic papillary renal cell carcinoma (PRCC), a rare type of kidney cancer. A clinical trial showed the drug was more effective than the current standard treatment.
-
Texting May Help Reduce Disparities in Colorectal Cancer ScreeningCombining text messaging with mailing people free at-home FIT kits helped increase screening for colorectal cancer among a predominantly Black population, a new study has found. It’s part of a larger effort to reduce disparities in cancer screening.
-
Hormone Therapy for Prostate Cancer? A Genetic Test Could Help DecideFor some men with prostate cancer, a genetic biomarker test called Decipher may help predict if their cancer will spread elsewhere in the body. The test could help determine whether hormone therapy, which can cause distressing side effects, is needed.
-
Commemorating the Contributions of Cancer Research GreatsFollowing the death of Dr. Emil Freireich in February, NCI Director Norman E. Sharpless reflects on the accomplishments and legacies of Dr. Freireich and several other cancer research luminaries who have passed in recent years.
-
Imaging Test Could Help Guide Breast Cancer Treatment DecisionsFor some people with ER-positive breast cancer, a new imaging test may help guide decisions about receiving hormone therapy, according to a new study. The test can show whether estrogen receptors in tumors are active and responsive to estrogen.
-
For Cancer Screening, COVID-19 Pandemic Creates Obstacles, OpportunitiesAfter a steep drop in screening for common cancers early in the COVID-19 pandemic, researchers are now exploring ways to improve cancer screening during the current crisis and beyond.